Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Number and Age-Adjusted Rate of Persons Aged ≥18 With Diagnosed Diabetes Who Began Treatment for End-Stage Renal Disease Attributed to Diabetes -- United States and Puerto Rico, 1996-2007

Incretin-based Agents

CV Safety of Incretin-based Therapies in Patients With T2D

CV Outcomes Studies With GLP-1 Agonists

Summary by Class: DPP-4 Inhibitors (Ongoing)

CV Outcomes Studies With SGLT2 Inhibitors

CV Outcomes Studies With Dual PPAR Agonists

Potential Pathophysiological Pathways of Insulin Leading to Hypertension

Mean Changes in Weight, Fitness, and CVD Risk Factors in ILI and DSE Groups and the Difference Between Groups Averaged Across 4 Years

ORIGIN Key Results

Diabetes as a Risk Factor for CV Events: Vascular Outcomes in T2D

Diabetes, Glucose, and CVD

Hyperglycemia on Admission Associated With Worse Outcomes

HPS: Subgroup Evaluation Shows Consistent Benefit in Patients With Diabetes Regardless of CVD

HPS: Consistent Benefit in Diabetic Patients Regardless of Baseline LDL-C

Multifactorial Management in Diabetes The Steno-2 Study -- 13 Years of Follow-up

Primary Prevention Trials With Aspirin in Diabetes

FREEDOM Trial: Inclusion Criteria

SAVOR-TIMI 53 Summary

SAVOR-TIMI 53 Summary

EXAMINE

EXAMINE

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)